Abstract
In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/m2/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS.
Article PDF
Avoid common mistakes on your manuscript.
References
Ransom JT. Mechanism of action of mycophenolate mofetil. Therap Drug Monit. 1995;17:68–84.
Zolezzi M. Mycophenolate sodium versus mycophenolate mofetil: A review of their comparative features. Saudi J Kidney Dis Transplant. 2005;16:140–5.
Indian Pediatrics Nephrology Group, Indian Academy of Pediatrics Management of steroid sensitive nephrotic syndrome: Revised guidelines. Indian Pediatr. 2008;45:203–14.
Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroiddependent nephrotic syndrome. Am J Kidney Dis. 2003;42:1114–20.
Banerjee S, Pahari A, Sengupta J, Patnaik SK. Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil. Pediatr Nephrol. 2013;28:93–7.
Afzal K, Bagga A, Menon S, Hari P, Jordan SC. Treatment with mycophenolate mofetil and prednisolone for steroiddependent nephrotic syndrome. Pediatr Nephrol. 2007;22:2059–65.
Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, et al. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: A Report from the southwest pediatric nephrology study group. Clin J Am Soc Nephrol. 2006;1:1173–8.
Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renaltransplant patients. Am J Transplant. 2004;4:231–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kapoor, K., Saha, A., Kaur, M. et al. Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome. Indian Pediatr 54, 885–886 (2017). https://doi.org/10.1007/s13312-017-1156-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-017-1156-5